NL-OMON41630已完成3 期
The safety and efficacy of Methylene Blue MMX® modified release tablets administered to subjects undergoing screening or surveillance colonoscopy. - Efficacy of Methylene Blue for screening/surveillance colonoscopy
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 272
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •* Males or females, aged between 50 and 75.
- •* A female is eligible to enter and participate in this study if she is: of non-childbearing potential including pre-menopausal females with documented (medical report verification) hysterectomy or double oophorectomy or postmenopausal.Or of child bearing potential, has a negative serum pregnancy test at screening and urine pregnancy test prior to start the study drug, and abstain completely from sexual intercourse or agrees to using highly effective contraceptive methods (e.g. intrauterine device, hormonal contraceptive drug, tubal ligation) during the study until completion of the follow-up procedures).
- •* Outpatients scheduled for screening or surveillance colonoscopy for polyps or colorectal cancer.
- •* Able to comprehend the full nature and purpose of the study, including possible risks and side effects.
- •* Able to co-operate with the investigator and to comply with the requirements of the entire study.
- •* Signed written informed consent prior to inclusion in the study.
- •* Patients taking psychiatric medications which could possibly interact with methylene blue are not to be included in the study if they have been taken up to 2 weeks prior to enrolment. Prozac is prohibited up to 5 weeks prior to enrolment.
- •* Patients will be included in accordance with the opinion of the countrywide screening committee.
排除标准
- •* Patients at high risk of colorectal cancer e.g. ulcerative colitis
- •* Pregnancy or lactation.
- •* Previous medical history of, or suspected hypersensitivity to, the Methylene Blue and/or formulations' ingredients.
- •* Previous medical history of, or suspected hypersensitivity to, the PEG based bowel cleansing preparation and/or bowel cleansing formulations' ingredients.
- •* Previous medical history of gastrointestinal obstruction or perforation, toxic megacolon, major colonic resection, severe diverticulitis, heart failure (Class III or IV), serious cardiovascular disease, ulcerative colitis or Crohn*s disease.
- •* ALT, AST, GGT, Bilirubin, Creatinine or Urea greater than 2.5 x the upper limit for normal range, based on local laboratory testing.
- •* The presence of serious cardiovascular disease, including very large abdominal aortic aneurysms (particularly if they are symptomatic), patients who are immediately postoperative, and patients who have suffered recent myocardial infarction (within 3 weeks), pulmonary embolism, or are currently hemodynamically unstable.
- •* The presence of liver disease with coagulopathy
- •* A history of anaemia (previously recorded haemoglobin of less than 10mg/dL) within the last 30 days prior to enrollment.
- •* Known or suspected deficiency of glucose-6-phosphate dehydrogenase,
- •* Known or suspected deficiency of NADPH reductase
- •* Treatment within 5 weeks prior to randomisation with Fluoxetine (Prozac).
- •* Concurrent treatment, or previous treatment within 2 weeks with any of the prohibited psychiatric medications that may interact with Methylene Blue as listed under Prohibited medications; Selective Serotonin Reuptake Inhibitors (SSRI), Serotonin-Norepinepherine Reuptake Inhibitors (SNRI*s), listed Tricyclic anti-depressants or Monoamine oxidase A inhibitors.
- •* Current enrollment in any other clinical trial, or previous enrollment in a clinical trial within the last 30 days.
- •* Other medical condition that in the investigators opinion would make the administration of the study drug or procedures hazardous to the subject.
- •* Men and women, between 50-75 years of age, who have accepted invitation to enrol in the national bowel cancer screening programme.
研究者
相似试验
进行中（未招募）
1 期
The safety and effectiveness of Methylene Blue MMX® tablets given to patients undergoing screening or surveillance colonoscopy.EUCTR2012-003983-32-DECosmo Technologies Ltd1,270
进行中（未招募）
1 期
The safety and effectiveness of Methylene Blue MMX® tablets given to patients undergoing screening or surveillance colonoscopy.EUCTR2012-003983-32-LTCosmo Technologies Ltd1,270
进行中（未招募）
1 期
The safety and effectiveness of Methylene Blue MMX® tablets given to patients undergoing screening or surveillance colonoscopy.EUCTR2012-003983-32-ITCosmo Technologies Ltd1,270
进行中（未招募）
1 期
The safety and effectiveness of Methylene Blue MMX® tablets given to patients undergoing screening or surveillance colonoscopy.EUCTR2012-003983-32-BECosmo Technologies Ltd1,270
进行中（未招募）
1 期
The safety and effectiveness of Methylene Blue MMX® tablets given to patients undergoing screening or surveillance colonoscopy.EUCTR2012-003983-32-NLCosmo Technologies Ltd1,270